Form 4 for LLY Lilly (Eli)
Accepted 2026-02-11 00:00:00 ET · period of report 2026-02-09 · accession 0001661254-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-11 | 2026-02-09 | LLY | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | A - Grant | $1,044.67 | +4,866 | 26.6K | +22% | +$5.08M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | A | A | 4,865.89 | $1,044.67 | 26,626.50 | D | — | — |